Shares of Inogen are sliding after short-seller Citron Research published a new cautious report on the company, contending that Inogen has the “lowest R&D spend” in medical technology, “no pipeline” and a “future that is guaranteed to have price compression and competition.” Andrew Left’s firm set a “generous” price target of $95 on Inogen shares, which are down 8% to $159.38 following the publication of the report.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.